Organization (Academic)
Baqiyatallah Medical Sciences University
ClinicalTrials.gov lists Baqiyatallah Medical Sciences University as lead sponsor of 31 trials. It has 10 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo MrInfo2012 This W3C-unspecified vector image was created with Inkscape ., via Wikimedia Commons, CC BY-SA 3.0. Shown to identify the organization; it may be a registered trademark.
This page covers Baqiyatallah Medical Sciences University: 31 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (31)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Bronchiolitis | 5 |
| COVID-19 | 3 |
| Diabetes Mellitus | 3 |
| Diabetes Mellitus, Type 2 | 3 |
| Pulmonary Disease, Chronic Obstructive | 3 |
Showing 5 of 31 disease areas.
Trials by start year as sponsor or collaborator (14)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 2 |
| 2023 | 1 |
| 2020 | 4 |
| 2019 | 1 |
| 2018 | 2 |
| 2017 | 2 |
| 2016 | 2 |
| 2015 | 1 |
| 2014 | 1 |
| 2012 | 2 |
Showing 10 of 14 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (10)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin) | 2 |
| Macrolid, Theophylline, Inhaler Corticosteroids | 1 |
| Erythromycin, Azithromycin , Clarithromycin | 1 |
| Neostigmine | 1 |
| Erythromycin | 1 |
Showing 5 of 10 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 0 of 1 hit target (n=1) | 1 of 1 on time (n=1) |
Journals published in (10)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| BMC cardiovascular disorders | 1 |
| BioMed research international | 1 |
| Critical care (London, England) | 1 |
| Haematologica | 1 |
| High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension | 1 |
Showing 5 of 10 journals.
Organization relationships (7)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Tabriz Research Center for Gastroenterology and Liver Diseases | Co sponsors trial with | 2 |
| Ministry of Health and Medical Education | Co sponsors trial with | 2 |
| Baqiyatallah Research Center for Gastroenterology and Liver Diseases | Co sponsors trial with | 2 |
| Tehran Hepatitis Center | Co sponsors trial with | 2 |
| Shahid Beheshti University of Medical Sciences | Co sponsors trial with | 1 |
Showing 5 of 7 relationships.
Latest dated events (29)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-10-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-07 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2023-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2020-08-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2020-08-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 29 events.
Biomarker capability evidence (3)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ANTXR2 | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted without stated criteria (ClinVar) |
| G6PD | Trial sponsor | Named in trial exclusion criteria |
| G6PD | Trial sponsor | Mentioned in trial text |
Biomarkers this organization publishes on (117)
Shown in this order: most publications first.
Showing 5 of 117 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.